- Home
- PDSB vs SNTI Comparison
PDSB vs SNTI Comparison
Compare PDSB & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- SNTI
- Stock Information
- Founded
- PDSB 2005
- SNTI 2016
- Country
- PDSB United States
- SNTI United States
- Employees
- PDSB N/A
- SNTI N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- PDSB Health Care
- SNTI Health Care
- Exchange
- PDSB Nasdaq
- SNTI Nasdaq
- Market Cap
- PDSB 72.2M
- SNTI 85.3M
- IPO Year
- PDSB N/A
- SNTI N/A
- Fundamental
- Price
- PDSB $1.62
- SNTI $2.17
- Analyst Decision
- PDSB Strong Buy
- SNTI Strong Buy
- Analyst Count
- PDSB 2
- SNTI 2
- Target Price
- PDSB $10.00
- SNTI $8.50
- AVG Volume (30 Days)
- PDSB 855.2K
- SNTI 323.7K
- Earning Date
- PDSB 08-12-2025
- SNTI 08-12-2025
- Dividend Yield
- PDSB N/A
- SNTI N/A
- EPS Growth
- PDSB N/A
- SNTI N/A
- EPS
- PDSB N/A
- SNTI N/A
- Revenue
- PDSB N/A
- SNTI N/A
- Revenue This Year
- PDSB N/A
- SNTI N/A
- Revenue Next Year
- PDSB N/A
- SNTI $150.00
- P/E Ratio
- PDSB N/A
- SNTI N/A
- Revenue Growth
- PDSB N/A
- SNTI N/A
- 52 Week Low
- PDSB $0.85
- SNTI $1.52
- 52 Week High
- PDSB $4.42
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- PDSB 54.15
- SNTI 33.12
- Support Level
- PDSB $1.53
- SNTI $2.56
- Resistance Level
- PDSB $1.85
- SNTI $3.40
- Average True Range (ATR)
- PDSB 0.14
- SNTI 0.43
- MACD
- PDSB -0.01
- SNTI -0.09
- Stochastic Oscillator
- PDSB 44.86
- SNTI 2.33
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.